Skip to main content

Advertisement

SpringerLink
Log in

Von Willebrand factor and thrombosis

  • Review Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

There is increasing evidence that von Willebrand factor (VWF), an adhesive multimeric protein that has an important function in primary hemostasis and as a carrier of factor VIII, has a pivotal role in thrombogenesis. In fact, while the presence in plasma of unusually large VWF multimers due to a congenital or acquired deficiency of a VWF-cleaving metalloprotease has been implicated in the pathogenesis of thrombotic thrombocytopenic purpura (TTP), high plasma levels of VWF have been associated with a slightly increased risk of arterial thrombosis. With regard to the association between VWF and venous thrombosis, clear conclusions cannot yet be drawn from the conflicting published data. Patients with von Willebrand disease, an inherited hemorrhagic disorder, may also paradoxically experience thrombotic events as a result of interactions among multiple prothrombotic risk factors. After a description of the structure and physiology of VWF, all these aspects are discussed in the present review.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Weiss HJ, Sussman II, Hoyer LW (1977) Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest 60:390–404

    Article  PubMed  CAS  Google Scholar 

  2. Sakariassen KS, Bolhuis PA, Sixma JJ (1979) Human blood platelet adhesion to artery subendothelium is mediated by factor VIII–Von Willebrand factor bound to the subendothelium. Nature 279:636–638

    Article  PubMed  CAS  Google Scholar 

  3. Martinelli I (2005) Von Willebrand factor and factor VIII as risk factors for arterial and venous thrombosis. Semin Hematol 42:49–55

    Article  PubMed  CAS  Google Scholar 

  4. Franchini M (2004) Thrombotic complications in patients with hereditary bleeding disorders. Thromb Haemost 92:298–304

    PubMed  CAS  Google Scholar 

  5. Soejima K, Nakagaki T (2005) Interplay between ADAMTS13 and von Willebrand factor in inherited and acquired thrombotic microangiopathies. Semin Hematol 42:56–62

    Article  PubMed  CAS  Google Scholar 

  6. Castaman G, Federici AB, Rodeghiero F, Mannucci PM (2003) Von Willebrand’s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment. Haematologica 88:94–108

    PubMed  CAS  Google Scholar 

  7. Mancuso DJ, Tuley EA, Westfield LA, Lester-Mancuso TL, Le Beau MM, Sorace JM, Sadler JE (1991) Human von Willebrand factor gene and pseudogene: structural analysis and differentiation by polymerase chain reaction. Biochemistry 30:253–269

    Article  PubMed  CAS  Google Scholar 

  8. Sadler JE, Mancuso DJ, Randi AM, Tuley EA, Westfield LA (1991) Molecular biology of von Willebrand factor. Ann NY Acad Sci 614:114–124

    Article  PubMed  CAS  Google Scholar 

  9. Mendolicchio GL, Ruggeri ZM (2005) New perspectives on von Willebrand factor functions in hemostasis and thrombosis. Semin Hematol 42:5–14

    Article  PubMed  CAS  Google Scholar 

  10. Wagner DD (1990) Cell biology of von Willebrand factor. Annu Rev Cell Biol 6:217–246

    Article  PubMed  CAS  Google Scholar 

  11. Ruggeri ZM (2003) Von Willebrand factor. Curr Opin Hematol 10:142–149

    Article  PubMed  CAS  Google Scholar 

  12. Dong JF, Moake JL, Nolasco L, Bernardo A, Arceneaux W, Shrimpton CN, Schade AJ, McIntire LV, Fujikawa K, Lopez JA (2002) ADAMTS-13 rapidly cleaves newly secreted ultralarge von Willebrand factor multimers on the endothelial surface under flowing conditions. Blood 100:4033–4039

    Article  PubMed  CAS  Google Scholar 

  13. Schmugge M, Rand ML, Freedman J (2003) Platelets and von Willebrand factor. Transfus Apher Sci 28:269–277

    Article  PubMed  Google Scholar 

  14. Ruggeri ZM (2001) Structure of von Willebrand factor and its function in platelet adhesion and thrombus formation. Best Pract Res Clin Haematol 14:257–279

    Article  PubMed  CAS  Google Scholar 

  15. Ruggeri ZM (2000) Old concepts and new developments in the study of platelet aggregation. J Clin Invest 105:699–701

    Article  PubMed  CAS  Google Scholar 

  16. Vlot AJ, Koppelman SJ, Bouma BN, Sixma JJ (1998) Factor VIII and von Willebrand factor. Thromb Haemost 79:456–465

    PubMed  CAS  Google Scholar 

  17. Cattaneo M (2001) Role of von Willebrand factor in atherothrombosis. Haematologica 86:3–5

    Google Scholar 

  18. Yamashita A, Asada Y, Sugimura H, Yamamoto H, Marutsuka K, Hatakeyama K, Tamura S, Ikeda Y, Sumiyoshi A (2003) Contribution of von Willebrand factor to thrombus formation on neointima of rabbit stenotic iliac artery under high blood-flow velocity. Arterioscler Thromb Vasc Biol 23:1105–1110

    Article  PubMed  CAS  Google Scholar 

  19. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr, Montgomery RR (1987) The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69:1691–1695

    PubMed  CAS  Google Scholar 

  20. Jeremic M, Weisert O, Gedde-Dahl TW (1976) Factor VIII (AHG) levels in 1016 regular blood donors. The effects of age, sex, and ABO blood groups. Scand J Clin Lab Invest 36:461–466

    Article  PubMed  CAS  Google Scholar 

  21. Mannucci PM (1998) Von Willebrand factor: a marker of endothelial damage? Arterioscler Thromb Vasc Biol 18:1359–1362

    PubMed  CAS  Google Scholar 

  22. Meade TW, Cooper JA, Stirling Y, Howarth DJ, Ruddock V, Miller GJ (1994) Factor VIII, ABO blood group and the incidence of ischaemic heart disease. Br J Haematol 88:601–607

    Article  PubMed  CAS  Google Scholar 

  23. Thompson SG, Kienast J, Pyke SD, Haverkate F, van de Loo JC (1995) Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 332:635–641

    Article  PubMed  CAS  Google Scholar 

  24. Folsom AR, Wu KK, Rosamond WD, Sharrett AR, Chambless LE (1997) Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 96:1102–1108

    PubMed  CAS  Google Scholar 

  25. Folsom AR, Rosamond WD, Shahar E, Cooper LS, Aleksic N, Nieto FJ, Rasmussen ML, Wu KK (1999) Prospective study of markers of hemostatic function with risk of ischemic stroke. The Atherosclerosis Risk in Communities (ARIC) Study Investigators. Circulation 100:736–742

    PubMed  CAS  Google Scholar 

  26. Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD (1997) Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study. Arterioscler Thromb Vasc Biol 17:3321–3325

    PubMed  CAS  Google Scholar 

  27. Rumley A, Lowe GD, Sweetnam PM, Yarnell JW, Ford RP (1995) Factor VIII, von Willebrand factor and the risk of major ischaemic heart disease in the Caerphilly Heart study. Br J Haematol 105:110–116

    Article  Google Scholar 

  28. Jansson JH, Nilsson TK, Johnson O (1998) Von Willebrand factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 80:334–337

    PubMed  CAS  Google Scholar 

  29. Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Rumley A, Lowe GD (2002) Von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 23:1764–1770

    Article  PubMed  CAS  Google Scholar 

  30. Jager A, van Hinsbergh VW, Kostense PJ, Emeis JJ, Yudkin JS, Nijpels G, Dekker JM, Heine RJ, Bouter LM, Stehouwer CD (1999) Von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study. Arterioscler Thromb Vasc Biol 19:3071–3078

    PubMed  CAS  Google Scholar 

  31. Morange PE, Simon C, Alessi MC, Luc G, Arveiler D, Ferrieres J, Amouyel P, Evans A, Ducimetiere P, Juhan-Vague I; on behalf of the PRIME study (2004) Endothelial cell markers and the risk of coronary heart disease: the Prospective Epidemiological Study of Myocardial Infarction (PRIME) study. Circulation 109:1343–1348

    Article  PubMed  CAS  Google Scholar 

  32. van der Meer IM, Brouwers GJ, Bulk S, Leebeek FW, van der Kuip DA, Hofman A, Witteman JC, Gomez Garcia EB (2004) Genetic variability of von Willebrand factor and risk of coronary heart disease: the Rotterdam Study. Br J Haematol 124:343–347

    Article  PubMed  Google Scholar 

  33. Sramek A, Bucciarelli P, Federici AB et al (2004) Patients with type 3 severe von Willebrand disease are not protected against atherosclerosis: results from a multicenter study in 47 patients. Circulation 109:740–744

    Article  PubMed  CAS  Google Scholar 

  34. Stead NW, Bauer KA, Kinney TR, Lewis JG, Campbell EE, Shifman MA, Rosenberg RD, Pizzo SV (1983) Venous thrombosis in a family with defective release of vascular plasminogen activator and elevated plasma factor VIII/von Willebrand’s factor. Am J Med 74:33–39

    Article  PubMed  CAS  Google Scholar 

  35. Nilsson T, Mellbring G, Hedner U (1986) Relationship between factor XII, von Willebrand factor and postoperative deep vein thrombosis. Acta Chir Scand 152:347–349

    PubMed  CAS  Google Scholar 

  36. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152–155

    Article  PubMed  CAS  Google Scholar 

  37. Tsai AW, Cushman M, Rosamond WD, Heckbert SR, Tracy RP, Aleksic N, Folsom AR (2002) Coagulation factors, inflammation markers, and venous thromboembolism: the longitudinal investigation of thromboembolism etiology (LITE). Am J Med 113:636–642

    Article  PubMed  Google Scholar 

  38. Bucek RA, Reiter M, Quehenberger P, Weltermann A, Kyrle PA, Minar E (2003) Thrombus precursor protein, endogenous thrombin potential, von-Willebrand factor and activated factor VII in suspected deep vein thrombosis: is there a place for new parameters? Br J Haematol 120:123–128

    Google Scholar 

  39. Kamphuisen PW, Eikenboom JC, Rosendaal FR, Koster T, Blann AD, Vos HL, Bertina RM (2001) High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 115:156–158

    Article  PubMed  CAS  Google Scholar 

  40. Moake JL (1998) Moschcowitz, multimers, and metalloprotease. N Engl J Med 339:1629–1631

    Article  PubMed  CAS  Google Scholar 

  41. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J, Kaketani K (1985) Immunohistochemistry of vascular lesion in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen. Thromb Res 38:469–479

    Article  PubMed  CAS  Google Scholar 

  42. Ruggenenti P, Noris M, Remuzzi G (2001) Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int 60:831–846

    Article  PubMed  CAS  Google Scholar 

  43. Tsai HM (2003) Deficiency of ADAMTS13 causes thrombotic thrombocytopenic purpura. Arterioscler Thromb Vasc Biol 23:388–396

    Article  PubMed  Google Scholar 

  44. Moake JL, Rudy CK, Troll JH, Weinstein MJ, Colannino NM, Azocar J, Seder RH, Hong SL, Deykin D (1982) Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura. N Engl J Med 307:1432–1435

    PubMed  CAS  Google Scholar 

  45. Furlan M, Robles R, Lämmle B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223–4234

    PubMed  CAS  Google Scholar 

  46. Tsai HM (1996) Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235–4244

    PubMed  CAS  Google Scholar 

  47. Furlan M, Robles R, Solenthaler M, Lämmle B (1998) Acquired deficiency of von Willebrand factor cleaving protease in a patient with thrombotic thrombocytopenic purpura. Blood 91:2839–2846

    PubMed  CAS  Google Scholar 

  48. Tsai HM, Lian EC (1998) Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585–1594

    Article  PubMed  CAS  Google Scholar 

  49. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lammle B (1998) Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. N Engl J Med 339:1578–1584

    Article  PubMed  CAS  Google Scholar 

  50. Veyradier A, Obert B, Houllier A, Meyer D, Girma JP (2001) Specific von Willebrand factor-cleaving protease in thrombotic microangiopathy: a study of 111 cases. Blood 98:1765–1772

    Article  PubMed  CAS  Google Scholar 

  51. Fujikawa K, Suzuki H, McMullen B, Chung D (2001) Purification of human von Willebrand factor cleaving protease and its identification as a new member of the metalloproteinase family. Blood 98:1662–1666

    Article  PubMed  CAS  Google Scholar 

  52. Gerritsen HE, Robles R, Lämmle B, Furlan M (2001) Partial amino acid sequence of purified von Willebrand factor-cleaving protease. Blood 98:1654–1661

    Article  PubMed  CAS  Google Scholar 

  53. Zheng X, Chung D, Takayama TK, Majerus EM, Sadler JE, Fujikawa K (2001) Structure of von Willebrand factor cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura. J Biol Chem 276:41059–41063

    Article  PubMed  CAS  Google Scholar 

  54. Plaimauer B, Zimemrmann K, Völkel D, Antoine G, Kerschbaumer R, Jenab P, Furlan M, Gerritsen H, Lammle B, Schwarz HP, Scheiflinger F (2002) Cloning, expression, and functional characterization of the von Willebrand factor-cleaving protease (ADAMTS13). Blood 100:3626–3632

    Article  PubMed  CAS  Google Scholar 

  55. Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM (2001) Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature 413:488–494

    Article  PubMed  CAS  Google Scholar 

  56. Bowen D, Dasani H, Yung B, Bloom A (1992) Deep venous thrombosis and pulmonary embolism in a patient with type III von Willebrand’s disease, protein C and antithrombin III deficiency. Br J Haematol 81:446–447

    Article  PubMed  CAS  Google Scholar 

  57. Franchini M, Krampera M, Veneri D (2003) Deep vein thrombosis after orthopedic surgery in a patient with type 1 von Willebrand disease and mutations in the MTHFR and beta-fibrinogen genes. Thromb Haemost 90:963–964

    PubMed  CAS  Google Scholar 

  58. Franchini M, Veneri D (2004) Are only hemophiliacs protected against ischemic heart disease? Thromb Haemost 92:1455–1456

    PubMed  CAS  Google Scholar 

  59. Fragasso G, Camba L, Pizzetti G, Pagnotta P, Chierchia SL (1998) Successful thrombolysis for acute myocardial infarction in type 1 von Willebrand’s disease (vWD). Am J Hematol 57:180

    Article  PubMed  CAS  Google Scholar 

  60. Mannucci PM (2002) Venous thromboembolism in von Willebrand disease. Thromb Haemost 88:378–379

    PubMed  CAS  Google Scholar 

  61. Sadler JE (2005) New concepts in von Willebrand disease. Annu Rev Med 56:173–1791

    Article  PubMed  CAS  Google Scholar 

  62. Ruggeri ZM (2004) Type IIB von Willebrand disease: a paradox explains how von Willebrand factor works. J Thromb Haemost 2:2–6

    Article  PubMed  CAS  Google Scholar 

  63. Savage B, Saldivar E, Ruggeri ZM (1996) Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor. Cell 84:289–297

    Article  PubMed  CAS  Google Scholar 

  64. Miura S, Li CQ, Cao Z, Wang H, Wardell MR, Sadler JE (2000) Interaction of von Willebrand factor domain A1 with platelet glycoprotein Ibalpha-(1-289). Slow intrinsic binding kinetics mediate rapid platelet adhesion. J Biol Chem 275:7539–7546

    Article  PubMed  CAS  Google Scholar 

  65. Makris M, Colvin B, Gupta V, Shields ML, Smith MP (2002) Venous thrombosis following the use of intermediate purity FVIII concentrate to treat patients with von Willebrand’s disease. Thromb Haemost 88:387–388

    PubMed  CAS  Google Scholar 

  66. Mannucci PM, Chediak J, Hanna W, Byrnes J, Marlies L, Ewenstein BM, and the Alphanate Study Group (2002) Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study. Blood 99:450–456

    Article  PubMed  CAS  Google Scholar 

  67. Franchini M, Rossetti G, Tagliaferri A, Pattacini C, Pozzoli D, Lippi G, Manzato F, Bertuzzo D, Gandini G (2003) Efficacy and safety of factor VIII/ von Willebrand factor concentrate (Haemate-P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand’s disease. Haematologica 88:1279–1283

    PubMed  CAS  Google Scholar 

  68. Rosendaal FR (2000) High levels of factor VIII and venous thrombosis. Throm Haemost 83:1–2

    CAS  Google Scholar 

  69. Mannucci PM (2004) Treatment of von Willebrand’s disease. N Engl J Med 35:683–694

    Article  Google Scholar 

  70. Basso IN, Keeling D (2004) Myocardial infarction following recombinant activated factor VII in a patient with type 2A von Willebrand disease. Blood Coagul Fibrinolysis 15:503–504

    Article  PubMed  Google Scholar 

  71. Goodnough LT, Saito H, Ratnoff OD (1983) Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: a report of 21 patients and a review of 50 previously reported cases. Medicine (Baltimore) 62:248–255

    CAS  Google Scholar 

  72. Dulhoste MN, Bonnet J, Vergnes C, Choussat A, Bricaud H (1989) Von Willebrand's disease and coronary atherosclerosis. Apropos of 3 cases. Arch Mal Coeur Vaiss 82:1875–1878

    PubMed  CAS  Google Scholar 

  73. Girolami A, Cappellato MG, Vicarioto MA, Casonato S, Marafioti F (1986) Associated von Willebrand disease as a possible cause of lack of thrombosis in an AT III abnormality (AT III Trento). Blut 52:29–33

    Article  PubMed  CAS  Google Scholar 

  74. van Dijk K, van der Bom JG, Fischer K, Grobbee DE, van der Berg HM (2004) Do prothrombotic factors influence clinical phenotype of severe hemophilia? A review of the literature. Thromb Haemost 92:305–310

    PubMed  Google Scholar 

  75. Weiss HJ (2004) The bleeding tendency in patients with low von Willebrand factor and type 1 phenotype is greater in the presence of impaired collagen-induced platelet aggregation. J Thromb Haemost 2:198–199

    Article  PubMed  CAS  Google Scholar 

  76. Kunicki TJ, Federici AB, Salomon DR, Koziol JA, Head SR, Mondala TS, Chismar JD, Baronciani L, Canciani MT, Peake IR (2004) An association of candidate gene haplotypes and bleeding severity in von Willebrand disease (VWD) type 1 pedigrees. Blood 104:2359–2367

    Article  PubMed  CAS  Google Scholar 

  77. Bond L, Bevan D (1988) Myocardial infarction in a patient with hemophilia treated with DDAVP. N Engl J Med 318:121

    PubMed  CAS  Google Scholar 

  78. Byrnes JJ, Larcada A, Moake JL (1988) Thrombosis following desmopressin for uremic bleeding. Am J Hematol 28:63–65

    Article  PubMed  CAS  Google Scholar 

  79. Mannucci PM, Lusher JM (1989) Desmopressin and thrombosis. Lancet 2:675

    Article  PubMed  CAS  Google Scholar 

  80. van Dantzig JM (1989) Desmopressin and myocardial infarction. Lancet 1:664–665

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Servizio di Immunoematologia e Trasfusione, Ospedale Policlinico, Azienda Ospedaliera di Verona, Piazzale L. Scuro, 10, 37134, Verona, Italy

    Massimo Franchini

  2. Istituto di Chimica e Microscopia Clinica, Dipartimento di Scienze Biomediche e Morfologiche, Università di Verona, Verona, Italy

    Giuseppe Lippi

Authors
  1. Massimo Franchini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Lippi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Franchini.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Franchini, M., Lippi, G. Von Willebrand factor and thrombosis. Ann Hematol 85, 415–423 (2006). https://doi.org/10.1007/s00277-006-0085-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-006-0085-5

Keywords

Search

Navigation